Safety of HEPLISAV™ Hepatitis B Virus Vaccine in End-stage Kidney Failure Patients

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE1

Total Enrollment

42 participants

Study Classification

INTERVENTIONAL

Study Start Date

2006-01-31

Study Completion Date

2008-03-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to find out if a new investigational hepatitis B virus vaccine, HEPLISAV™, is safe in patients at least 40 years of age who have progressive loss of kidney function with more advanced stage 3 (GFR ≤ 45 mL/min) or stage 4 chronic kidney disease, and are expected to eventually go on hemodialysis.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

A Safety and Efficacy Study of a Single or Double Dose of HEPLISAV™ Hepatitis B Vaccine in Adults With End-Stage Renal Disease

NCT00498212

Hepatitis B

TERMINATED PHASE2

Comparing Safety and Immunogenicity of HEPLISAV-B® to Engerix-B® in Chronic Kidney Disease (CKD) Patients

NCT00985426

Chronic Kidney Disease

COMPLETED PHASE3

Long-Term Study on Safety and Immunogenicity of HEPLISAV™ and Engerix-B® in Adults With Chronic Kidney Disease

NCT01282762

Chronic Kidney Disease

COMPLETED

Safety and Immunogenicity of HEPLISAV™ a Hepatitis B Virus Vaccine in Adults on Hemodialysis

NCT01195246

End Stage Renal Disease

COMPLETED PHASE3

Safety and Immunogenicity Study of the Hepatitis B Virus (HBV) Vaccine, HEPLISAV Compared to Engerix-B Vaccine

NCT01005407

Healthy

COMPLETED PHASE3

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Infection with hepatitis B virus (HBV) is a major global health problem. Worldwide, it is estimated that 2 billion people have been infected previously and 350 million are chronically infected. About 25% of people who do not initially clear the infection will later develop chronic active hepatitis. Hemodialysis and pre-dialysis patients with kidney failure have multiple immune defects that make them more likely to develop a chronic infection. In addition, hemodialysis increases the risk of exposure to HBV. Existing HBV vaccines are effective in preventing infection in healthy adults. However, poor responses occur in people who are over 40 years of age and have end-stage kidney failure.

This study will evaluate the safety, tolerability and immune response of three escalating dose levels of HEPLISAV™, compared with a commercially available HBV vaccine, Engerix-B®, in patients at least 40 years of age who have progressive loss of kidney function with more advanced stage 3 (GFR ≤ 45 mL/min) or stage 4 chronic kidney disease and are expected to eventually go on hemodialysis. About 72 patients will be included in the study. Once patients have been consented, screened, and randomized to treatment, they will receive four injections over a 24-week period, with follow-up visits at 28 and 50 weeks. Safety and tolerability will be evaluated by occurrence of adverse events, periodic laboratory tests, vital signs, and local/systemic reactogenicity.

Comparison: Patients will receive treatment with one of three escalating dose levels of HEPLISAV™ or the comparator vaccine, Engerix-B®.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Hepatitis B

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

PREVENTION

Blinding Strategy

SINGLE

Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

1

Low dose

Group Type EXPERIMENTAL

1018 ISS immunostimulatory oligonucleotide with HBV surface antigen

Intervention Type BIOLOGICAL

Intramuscular (IM) injections on Day 0, Week 4 and Week 24, plus a placebo (salt solution) injection at Week 8

2

Middle dose

Group Type EXPERIMENTAL

1018 ISS immunostimulatory oligonucleotide with HBV surface antigen

Intervention Type BIOLOGICAL

Intramuscular (IM) injections on Day 0, Week 4 and Week 24, plus a placebo (salt solution) injection at Week 8

3

High dose

Group Type EXPERIMENTAL

1018 ISS immunostimulatory oligonucleotide with HBV surface antigen

Intervention Type BIOLOGICAL

Intramuscular (IM) injections on Day 0, Week 4 and Week 24, plus a placebo (salt solution) injection at Week 8

4

Group Type ACTIVE_COMPARATOR

Hepatitis B Vaccine (Recombinant)

Intervention Type BIOLOGICAL

IM (in the muscle) injections on Day 0, Week 4, Week 8 and Week 24

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

1018 ISS immunostimulatory oligonucleotide with HBV surface antigen

Intramuscular (IM) injections on Day 0, Week 4 and Week 24, plus a placebo (salt solution) injection at Week 8

Intervention Type BIOLOGICAL

Hepatitis B Vaccine (Recombinant)

IM (in the muscle) injections on Day 0, Week 4, Week 8 and Week 24

Intervention Type BIOLOGICAL

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

HEPLISAV™ ENGERIX-B®

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Willing and able to give written informed consent
* Progressive loss of kidney function with more advanced stage 3 (GFR at least 45 mL/min) or stage 4 chronic kidney disease by National Kidney Foundation classification, and are expected to eventually go on hemodialysis
* Body mass index of 31 or less

Exclusion Criteria

* Received previous vaccination with any HBV vaccine (1 or more doses)
* Any history of HBV infection
* Pregnant or breast-feeding, or planning a pregnancy during the study
* Has autoimmune disease
* Diagnosis of chronic kidney failure due to autoimmune disease
* Receiving hemodialysis treatment at the time of enrollment
* Received any blood products or antibodies within 3 months prior to study entry, or is likely to require blood products during the study
* Ever received an injection with DNA plasmids or oligonucleotides
* Received erythropoietin within 7 days prior to the first study injection
* Received vaccination with any vaccines during the 4 weeks prior to study entry
* Received any other investigational medicinal agent during the 4 weeks prior to study entry

Minimum Eligible Age

40 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No